BR112015013349A2 - trieptanoína para o tratamento de deficiência de transportador de glicose 1 - Google Patents

trieptanoína para o tratamento de deficiência de transportador de glicose 1

Info

Publication number
BR112015013349A2
BR112015013349A2 BR112015013349A BR112015013349A BR112015013349A2 BR 112015013349 A2 BR112015013349 A2 BR 112015013349A2 BR 112015013349 A BR112015013349 A BR 112015013349A BR 112015013349 A BR112015013349 A BR 112015013349A BR 112015013349 A2 BR112015013349 A2 BR 112015013349A2
Authority
BR
Brazil
Prior art keywords
trieptanoin
treatment
glucose transporter
transporter deficiency
fatty acid
Prior art date
Application number
BR112015013349A
Other languages
English (en)
Inventor
Mochel Fanny
Schiffmann Raphael
Original Assignee
Baylor Res Institute At Dallas
National Institute Of Health And Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Institute At Dallas, National Institute Of Health And Medical Res filed Critical Baylor Res Institute At Dallas
Publication of BR112015013349A2 publication Critical patent/BR112015013349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computerised tomographs
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/501—Clinical applications involving diagnosis of head, e.g. neuroimaging, craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

resumo trieptanoína para o tratamento de deficiência de transportador de glicose 1 são fornecidos métodos para tratar glut1 e deficiências energéticas cerebrais relacionadas que compreendem administrar fontes de ácidos graxos com número ímpar de carbonos, por exemplo, fontes de ácidos graxos c5 ou c7 e composições relacionadas. 1/1
BR112015013349A 2012-12-13 2013-12-13 trieptanoína para o tratamento de deficiência de transportador de glicose 1 BR112015013349A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737013P 2012-12-13 2012-12-13
US201361779942P 2013-03-13 2013-03-13
PCT/US2013/075146 WO2014093901A1 (en) 2012-12-13 2013-12-13 Triheptanoin for the treatment of glucose transporter 1 deficiency

Publications (1)

Publication Number Publication Date
BR112015013349A2 true BR112015013349A2 (pt) 2017-07-11

Family

ID=50935011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013349A BR112015013349A2 (pt) 2012-12-13 2013-12-13 trieptanoína para o tratamento de deficiência de transportador de glicose 1

Country Status (13)

Country Link
US (3) US9468229B2 (pt)
EP (1) EP2931269B1 (pt)
JP (2) JP2016504323A (pt)
KR (1) KR20150095704A (pt)
CN (1) CN104955450A (pt)
AU (2) AU2013358951C1 (pt)
BR (1) BR112015013349A2 (pt)
CA (1) CA2894456C (pt)
ES (1) ES2728727T3 (pt)
HK (1) HK1216717A1 (pt)
IL (1) IL239330B (pt)
MX (1) MX2015007584A (pt)
WO (1) WO2014093901A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR20150095704A (ko) 2012-12-13 2015-08-21 베일러 리서치 인스티튜트 글루코스 수송체 1 결핍증의 치료를 위한 트라이헵타노인
MY177028A (en) 2013-11-14 2020-09-02 Ultragenyx Pharmaceutical Inc Solid compositions of triglycerides and uses thereof
EP3689343A1 (en) 2013-11-14 2020-08-05 The University of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof using anaplerotic agents
JP2017521464A (ja) * 2014-07-24 2017-08-03 バイエル・ファルマ・アクティエンゲゼルシャフト グルコース輸送阻害剤
WO2016164521A1 (en) * 2015-04-07 2016-10-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for treatment of movement disorders
US11337945B2 (en) 2016-06-01 2022-05-24 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
KR20190017873A (ko) 2016-06-08 2019-02-20 썬리겐 헬쓰케어 아게 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도
US11350870B2 (en) * 2017-06-20 2022-06-07 The Board Of Trustees Of The University Of Illinois Method of identifying epileptic brain regions
WO2019098377A1 (ja) 2017-11-20 2019-05-23 富士通化成株式会社 複合伝熱部材、及び複合伝熱部材の製造方法
WO2020127178A1 (en) * 2018-12-18 2020-06-25 Société des Produits Nestlé S.A. Dietary propionate
EP3845229A1 (en) * 2019-12-30 2021-07-07 Gliapharm SA Isoquinoline derivatives for use in treating glut1 deficiency syndrome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025649A (en) 1974-08-19 1977-05-24 Labaz Acetic acid derivatives having pharmacological activity and compositions containing the same
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
GB2104079B (en) 1981-08-14 1985-08-21 London Polytech New aminoacid isomers, their production and their medicinal use
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6740679B1 (en) 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
JP4902906B2 (ja) 1999-02-05 2012-03-21 ベイラー リサーチ インスティテュート 炭素数が７である脂肪酸を含むトリグリセリドを含有する栄養補助剤または医薬調製物
WO2001032168A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2323940T3 (es) 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
CA2517929A1 (en) 2003-03-06 2004-09-16 Accera Inc. Novel-chemical entities and methods for their use in treatment of metabolic disorders
EP1628622A4 (en) 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
CA2784420C (en) 2004-07-02 2020-11-10 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
WO2006037069A1 (en) 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
EP2338881A1 (en) 2005-02-23 2011-06-29 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
HUE040002T2 (hu) 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
KR20090074221A (ko) 2006-09-26 2009-07-06 베일러 리서치 인스티튜트 영양물 센서
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
PT2650381T (pt) 2007-07-31 2016-12-29 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
WO2009124250A1 (en) 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting tricarboxylic acid (tca) metabolic flux
MX348036B (es) * 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
US20110306663A1 (en) 2010-06-14 2011-12-15 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
KR101955001B1 (ko) 2010-12-23 2019-03-07 아마젠티스 에스에이 미토콘드리아 기능을 개선하고 신경퇴화 질환들 및 인지 장애들을 치료하는 조성물들 및 방법들
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
KR20150095704A (ko) 2012-12-13 2015-08-21 베일러 리서치 인스티튜트 글루코스 수송체 1 결핍증의 치료를 위한 트라이헵타노인
EP3689343A1 (en) 2013-11-14 2020-08-05 The University of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof using anaplerotic agents
WO2016164521A1 (en) 2015-04-07 2016-10-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for treatment of movement disorders

Also Published As

Publication number Publication date
IL239330A0 (en) 2015-07-30
AU2013358951C1 (en) 2019-06-27
EP2931269B1 (en) 2019-05-15
US20140221482A1 (en) 2014-08-07
KR20150095704A (ko) 2015-08-21
US9468229B2 (en) 2016-10-18
US20160374980A1 (en) 2016-12-29
CA2894456C (en) 2022-06-28
AU2018202336A1 (en) 2018-04-26
ES2728727T3 (es) 2019-10-28
JP2016504323A (ja) 2016-02-12
EP2931269A4 (en) 2016-07-27
IL239330B (en) 2018-05-31
AU2013358951A1 (en) 2015-07-02
AU2013358951B2 (en) 2018-02-01
CN104955450A (zh) 2015-09-30
WO2014093901A1 (en) 2014-06-19
US10111848B2 (en) 2018-10-30
MX2015007584A (es) 2016-03-15
EP2931269A1 (en) 2015-10-21
HK1216717A1 (zh) 2016-12-02
JP2018131470A (ja) 2018-08-23
CA2894456A1 (en) 2014-06-19
US20190290610A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
CR20150217A (es) Inhibidores de histona demetilasas
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
BR112014019990A8 (pt) Compostos enediinos, seus conjugados e usos e métodos para esses compostos
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112015023603A2 (pt) métodos de uso do zscan4 para rejuvenescer células humanas
BR112015020904A2 (pt) microrganismos e métodos para produção de butadieno e compostos relacionados por assimilação de formiato
BR112013026976A2 (pt) alfa glucosidade ácida modificada com processamento acelerado
MX2019003619A (es) Formulaciones de bromocriptina.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
IN2014DN08385A (pt)
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]